WO2020055359A3 - Forme posologique orale de tosylate de sorafénib - Google Patents
Forme posologique orale de tosylate de sorafénib Download PDFInfo
- Publication number
- WO2020055359A3 WO2020055359A3 PCT/TR2019/050578 TR2019050578W WO2020055359A3 WO 2020055359 A3 WO2020055359 A3 WO 2020055359A3 TR 2019050578 W TR2019050578 W TR 2019050578W WO 2020055359 A3 WO2020055359 A3 WO 2020055359A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- dosage form
- oral dosage
- sorafenib tosylate
- present
- sorafenib
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Inorganic Chemistry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Abstract
L'invention concerne une forme posologique orale comprenant du tosylate de sorafénib en tant que principe actif qui présente des propriétés améliorées. La présente invention concerne également un procédé de préparation de ladite composition.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
TR2018/11686 | 2018-08-10 | ||
TR201811686 | 2018-08-10 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2020055359A2 WO2020055359A2 (fr) | 2020-03-19 |
WO2020055359A3 true WO2020055359A3 (fr) | 2020-06-04 |
Family
ID=69776588
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/TR2019/050578 WO2020055359A2 (fr) | 2018-08-10 | 2019-07-16 | Forme posologique orale de tosylate de sorafénib |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2020055359A2 (fr) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2023155182A1 (fr) * | 2022-02-21 | 2023-08-24 | 北京睿创康泰医药研究院有限公司 | Formulation orale de sorafénib ou de donafénib à faible dose et à exposition de forte intensité, et son utilisation |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030125359A1 (en) * | 2001-12-04 | 2003-07-03 | Lyons John F. | RAF-MEK-ERK pathway inhibitors to treat cancer |
WO2007059154A2 (fr) * | 2005-11-14 | 2007-05-24 | Bayer Healthcare Llc | Traitement de cancers a resistance acquise a des inhibiteurs de kit |
-
2019
- 2019-07-16 WO PCT/TR2019/050578 patent/WO2020055359A2/fr active Application Filing
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030125359A1 (en) * | 2001-12-04 | 2003-07-03 | Lyons John F. | RAF-MEK-ERK pathway inhibitors to treat cancer |
WO2007059154A2 (fr) * | 2005-11-14 | 2007-05-24 | Bayer Healthcare Llc | Traitement de cancers a resistance acquise a des inhibiteurs de kit |
Also Published As
Publication number | Publication date |
---|---|
WO2020055359A2 (fr) | 2020-03-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG11202105850YA (en) | Diphenyl-like compound, intermediate thereof, preparation method therefor, pharmaceutical composition thereof and uses thereof | |
WO2015120110A3 (fr) | Nouvelles formulations pharmaceutiques | |
WO2015160843A8 (fr) | Activateurs des canaux ioniques et leurs procédés d'utilisation | |
MX2021006697A (es) | Composición y método para el crecimiento del cabello. | |
PH12020550341A1 (en) | Niraparib formulations | |
EP3279207A4 (fr) | Nouveau composé de 4'-thionucléoside, ainsi que son procédé de préparation, composition pharmaceutique comprenant celui-ci et son application | |
WO2020127819A3 (fr) | Composition pharmaceutique comprenant de l'apixaban | |
MX2019012454A (es) | Compuesto solido cristalino novedoso de clorhidrato de 3-fenil-4-propil-1-(piridin-2-il)-1h-pirazol-5-ol. | |
PH12020550125A1 (en) | Crystalline forms of 3-substituted 1,2,4-oxadiazole | |
EP4327880A3 (fr) | Forme à l'état solide de succinate de ribociclib | |
PH12017502376A1 (en) | Oral solid formulation containing irinotecan and method of preparing the same | |
IL289763A (en) | Compounds, pharmaceutical compounds and methods for preparing compounds and their use | |
EP3760195A4 (fr) | Composition comprenant du 2,3-butanediol en tant que principe actif | |
WO2019194773A3 (fr) | Combinaison contenant de la linagliptine et de la metformine | |
EP4053152A4 (fr) | Kératine bd-13, procédé de préparation, composition pharmaceutique et utilisation de celle-ci | |
EP3539978A4 (fr) | Fragment de nkx3.2 et composition pharmaceutique le comprenant en tant que principe actif | |
EP3889160A4 (fr) | Composé de thiamine, son procédé de préparation et composition pharmaceutique associée | |
WO2016006975A3 (fr) | Nouveaux dérivés imidazotriazinone ou imidazopyrazinone et leur utilisation | |
WO2016006974A3 (fr) | Nouveaux dérivés triazolopyrimidinone ou triazolopyridinone et leur utilisation | |
EP4053151A4 (fr) | Kératine bd-1, procédé de préparation, ainsi que composition pharmaceutique et utilisation de celle-ci | |
WO2020055359A3 (fr) | Forme posologique orale de tosylate de sorafénib | |
MX2022005798A (es) | Red de nanohilos. | |
WO2017064652A3 (fr) | Compositions de dipyridamole faiblement dosées à administration orale et utilisations associées | |
EA201991286A1 (ru) | Твердая фармацевтическая композиция для перорального применения, содержащая тенофовир и эмтрицитабин | |
EP4053158A4 (fr) | Kératine bd-11, procédé de préparation et composition pharmaceutique et utilisation de celle-ci |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 19860306 Country of ref document: EP Kind code of ref document: A2 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 19860306 Country of ref document: EP Kind code of ref document: A2 |